Table 1.

Demographic and clinical data of melanoma patients¹ included in this study.

	(n=)	OP (weeks)	Age (mean)	Gender	25(OH)D s.c. (ng/ml)2		Survival3 (weeks)		Tumor load4		Adverse events (side effects ratio)5	Mutation status (wt/mut)6
					Baseline2 (mean)	Average2	OS	PFS	LDH (U/L)(Baseline2/Average2)	S100 (µg/L)		BRAF	NRAS	c-KIT
All patients1	83	54.32	63.43	45m 38f	19.61	21.05	100.66/97.00	53.94/34.00	321.6/344.0	0.74/1.02	0.5438	24	22	3
25(OH)D s.c. <10 ng/ml	13	25.30	63.15	7m 6f	7.2	7.36	29.59/19.00	20.30/12.00	419.5/490.1	1.51/2.35	0.6982	3	6	0
25(OH)D s.c. ≥10 ng/ml	70	59.78	63.49	38m 32f	22.05	23.71	112.04/117.00	60.83/48.00	305.0/319.3	0.6/0.77	0.518	21	16	3
BRAF wt	59	53.28	66.53	32m 27f	15.83	20.48	109.29/97.00	54.07/33.00	299.1/330.5	0.7/1.02	0.6156
25(OH)D s.c. <10 ng/ml	10	24.20	68.10	6m 4f	7.45	7.59	29.92/19.00	14.09/11.00	413.6/491.3	1.60/2.62	0.7680
25(OH)D s.c. ≥10 ng/ml	49	59.22	66.2	26m 23f	17.58	23.11	121.23/142.00	61.52/48.00	275.2/297.7	0.50/0.69	0.5845
BRAF mut	24	56.96	55.83	13m 11f	30.02	22.64	83.98/63.00	57.00/60.00	394.3/391.0	0.89/1.02	0.308
25(OH)D s.c. <10 ng/ml	3	29.00	46.67	1m 2f	6.37	6.58	29.00/16.00	37.00/13.00	N.A.7	1.02/1.02	N.A.7
25(OH)D s.c. ≥10 ng/ml	21	61.15	57.14	12m 9f	33.97	25.32	93.40/68.00	60.85/34.00	389.4/385.6	0.87/1.02	0.3265
Treatment modalities1
BRAF-/MEK- inhibitors1	19	62.42	56.05	9m 10f	31.5	22.9	81.77/62.00	54.70/34.00	310.57/287.9	0.24/0.58	0.4062	18	0	0
Immunotherapy1
CTLA-4 and PD-1 inhibitors	16	46.25	48.13	7m 9f	32.68	22.54	82.53/97.00	43.62/48.00	393.5/419.6	1.18/1.34	0.8150	6	4	2
CTLA-4-inhibitors	13	103.23	60.77	4m 9f	12.31	21.66	108.87/78.00	47.97/22.00	270.9/297.7	0.54/0.76	0.6738	1	5	0
PD-1 inhibitors	63	60.56	67.17	34m 29f	16.52	21.44	106.62/97.00	55.44/33.00	294.3/318.3	0.59/0.91	0.4844	12	19	1
	Patients with Metastases before therapy (n=)					other	Total number of metastasized organs	Total number of metastasized organs/number of patients
	(n=)	brain	lung	liver	skin/soft tissue
All patients1	82	19	50	25	29	39	162	1.95
25(OH)D s.c. < 10 ng/mL	13	5	10	5	3	6	29	2.23
25(OH)D s.c. ≥ 10 ng/mL	69	14	40	20	26	33	133	1.92
BRAF and MEK inhibitors	19	5	8	4	3	13	33	1.7
Immunotherapy1
CTLA-4 and PD-1 inhibitors	16	5	7	5	2	11	30	1.88
CTLA-4-inhibitors	13	3	9	3	6	5	26	2
PD-1 inhibitors	63	16	40	16	27	30	129	2.04

¹For treatment modalities, please see Table 2 .

²25(OH)D serum concentrations were investigated as described in the Methods. In short, 25(OH)D serum concentration was either assessed when starting therapy with ICIs or BRAFi/MEKi [“baseline 25(OH)D”] or calculated as average value of all 25(OH)D serum concentrations that were measured for each patient during the complete observation period [“average 25(OH)D”].

³Mean and Median Survival Estimates was assessed as described in the Methods.

⁴Tumor load was estimated by analyzing serum concentrations of LDH and S100 protein, as described in the Methods.

⁵Adverse events were assessed according to CTCAE criteria as described in the Methods.

⁶Mutation status was assessed as described in the Methods.

⁷Missing data due to small case number.

BRAF, B-rapidly accelerated fibrosarcoma; CTCAE, common terminology criteria for adverse events; CTLA, cytotoxic T-lymphocyte-associated protein; LDH, lactate dehydrogenase; MEK, mitogen-activated protein kinase kinase; Mut, mutated; OP, observation period; 25(OH)D s.c., 25(OH)D serum concentration; OS, overall survival; PD, programmed cell death protein; PFS, progress-free survival; TL, tumor load; wt, wild-type.

Rounding errors may occur in the data table. The number of patients may differ from the total sample size owing to missing data.